APA (7th ed.) Citation

Kumar, S., & Goldschmidt, H. (2019). Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma. Leukemia and lymphoma, 60(1), . https://doi.org/10.1080/10428194.2018.1459609

Chicago Style (17th ed.) Citation

Kumar, Shaji, and Hartmut Goldschmidt. "Propensity Score Matching Analysis to Evaluate the Comparative Effectiveness of Daratumumab Versus Real-world Standard of Care Therapies for Patients with Heavily Pretreated and Refractory Multiple Myeloma." Leukemia and Lymphoma 60, no. 1 (2019). https://doi.org/10.1080/10428194.2018.1459609.

MLA (9th ed.) Citation

Kumar, Shaji, and Hartmut Goldschmidt. "Propensity Score Matching Analysis to Evaluate the Comparative Effectiveness of Daratumumab Versus Real-world Standard of Care Therapies for Patients with Heavily Pretreated and Refractory Multiple Myeloma." Leukemia and Lymphoma, vol. 60, no. 1, 2019, https://doi.org/10.1080/10428194.2018.1459609.